INTRODUCTION 84 85
Pathogen-specific antibodies can prevent infection by numerous human viruses (1, 2) . 86
For HIV-1, neutralizing antibodies to the gp120 and gp41 envelope glycoproteins (Env) can 87 prevent infection in the macaque simian/human immunodeficiency virus (SHIV) model of 88 infection (3-10). Initial studies suggested high levels of antibodies were required for protection, 89 but more recent studies suggest that lower, physiologically achievable levels of plasma antibody 90 can prevent infection against mucosal challenge (8, 9, 11). While no human passive prevention 91 studies have so far been conducted with HIV-1-specific neutralizing monoclonal antibodies 92 (mAbs), the available animal model data suggest that neutralizing antibodies induced by a 93 vaccine or passive immunization could prevent human HIV-1 infection (12, 13). Advances in B-94 cell immunology and cloning techniques have led to the isolation of numerous HIV-1 95 neutralizing mAbs with potency and breadth far greater than earlier antibodies These antibodies 96 target multiple sites of vulnerability on the HIV-1 Env (14) including the CD4-binding site, the 97 V1V2 region and a glycan V3 site of gp120, the membrane-proximal external region of gp41, 98 and three newly described sites that include regions of both gp120 and gp41 . 99
Among these mAbs is VRC01, a CD4-binding site-directed antibody that neutralizes 100 ~90% of HIV-1 strains with a 50% inhibitory concentration (IC 50 ) less than 50 μg/ml and 72% of 101 HIV-1 strains with an IC 50 less than 1 μg/ml (19). The crystal structure of VRC01 bound to 102 gp120 reveals a mode of antibody recognition similar to the recognition of gp120 by the cell 103 surface receptor CD4 (20) . Additional mAbs that share genetic and structural characteristics with 104 VRC01 have been discovered (24, 26, 39) , and these mAbs have been collectively termed the 105 "VRC01-class" of neutralizing antibodies (14, 34, 40) . VRC01 is able to protect macaques 106 on July 10, 2017 by guest http://jvi.asm.org/ Downloaded from against vaginal or rectal SHIV challenge (41), a topical gel formulation is able to protect 107 humanized mice from HIV-1 challenge (42), and gene-based production of VRC01 from an 108 adeno-associated virus vector is able to protect humanized mice against HIV-1 infection (43, 44) . 109
Together, these data suggest that VRC01 may prevent infection in humans. 110
In addition to their potential to prevent infection, HIV-1 mAbs may have a role as 111 therapeutic agents. Several recent studies in NHP (45, 46) and humanized mouse models (47, 48) 112 indicate that combinations of potent HIV-1 mAbs could substantially reduce plasma viremia. 113
These studies also suggested that the magnitude of the in vivo therapeutic effect on viremia was 114 related to the in vitro neutralization potency of the antibodies. Prior NHP studies have also 115
suggested that infection could be prevented by passive infusion of neutralizing, but not non-116 neutralizing, HIV-1 specific antibodies (3, 49, 50). 117
We hypothesized that in vitro neutralization potency of an HIV-1 specific mAb would 118 correlate with its ability to prevent infection in vivo and therefore sought to improve the 119 neutralization potency and breadth of reactivity of antibody VRC01. Although various HIV-1 120 specific mAbs, including new, more potent mAbs (11, 41) been evaluated in NHPs, a direct 121 comparison between a wild-type and a higher potency engineered variant has not been 122 performed. Here, we used next generation sequencing of antibody gene transcripts to identify 123 heavy chain somatic variants of VRC01 with enhanced neutralization potency. The somatic 124 variant with highest potency, VRC07, was subjected to an iterative process of computational and 125 structure-guided optimization that identified mutations that optimized neutralization potency and 126 minimized autoreactivity in vitro. This process led to the selection of next generation VRC07 127 variants that allowed us to determine whether increased virus neutralization in vitro conferred 128 and remained antiretroviral treatment naïve with CD4 T-cell counts over 500 cells/μl and plasma 142 HIV-1 RNA loads less than 15,000 copies/ml. 143
144

Sample preparation for 454 pyrosequencing 145
The 454 library preparation and pyrosequencing of heavy chain transcripts was performed at the 146 NIH Sequencing Center (NISC), as previously described (26). Briefly, mRNA was extracted 147 from 20 million PBMCs into 200 µl elution buffer using the Oligotex Direct mRNA Mini Kit 148 (Qiagen), then concentrated to 10-30 µl by centrifuging the buffer through a 30 kD micron filter 149 (Millipore). Reverse transcription was performed in one or multiple 35 µl reactions, each 150 composed of 13 µl of mRNA, 3 µl of oligo(dT) 12-18 at 0.5 µg/µl (Invitrogen), 7 µl of 5x first-151 strand buffer (Invitrogen), 3 µl of RNaseOut (Invitrogen), 3 µl of 0.1 M DTT (Invitrogen), 3 µl 152 of dNTP mix (each at 10 mM), and 3 µl of SuperScript II (Invitrogen). The reactions were 153 incubated at 42°C for 2 h. The cDNAs from each reaction were combined, applied to the 154 NucleoSpin Extract II Kit (Clontech), and eluted in 20 µl of elution buffer. In this way, 1 µl of 155 7 the cDNA comprised transcripts from one million PBMCs. The immunoglobulin VH1 gene 156 family PCR was set up in a total volume of 50 µl, using 5 µl of the cDNA as template 157 (equivalent of transcripts from 5 million PBMCs). The DNA polymerase system used was the 158 Platinum Taq High-Fidelity (HiFi) system (Invitrogen). In accordance with the manufacturer's 159 instructions, the reaction mix was composed of water, 5 µl of 10x buffer, and 1 µl of supplied 160
MgSO 4 , 2 µl of dNTP mix (each at 10 mM), 1-2 µl of primers at 25 µM, and 1 µl of Platinum 161
Taq HiFi DNA polymerase. The forward primers for VH1 gene amplification were a mix of 162
3'; and 5'L-VH1-69, 5-'GGCAGCAGCTACAGGTGTCCAGTCC-3'. The reverse primers were 165 3'Cγ-CH1, 5'-GGGGGAAGACCGATGGGCCCTTGGTGG-3'; and 3'Cμ-CH1, 5'-166 GGGAATTCTCACAGGAGACGA-3'. We should note that the VH1 forward primers used for 167 this PCR were based on the unmutated germline human VH1 gene sequences, annealing at the 3' 168 end of the leader region or at the first three residues in the coding region. For heavily somatically 169 hypermutated heavy chain sequences such as those found in the VRC01-class, somatic 170 hypermutations in these regions will affect the PCR amplification efficiency as reported (24) . 171
The PCRs were initiated at 95°C for 30 s, followed by 25 cycles of 95°C for 30 s, 58°C for 30 s, 172 and 72°C for 1 min, then incubated at 72°C for 10 min. The PCR products at the expected size 173 (~500 bp) were gel extracted and purified (Qiagen), followed by further phenol/chloroform 174 extraction (52). Crystallization, data collection, and structure determination 215 VRC07 heavy chain gene with an HRV3C cleavage site (GLEVLFQGP) after Lys 235 was 216 synthesized and cloned into the pVRC8400 vector. VRC01 light chain gene was synthesized and 217 cloned into the same vector, and an Asn72Thr mutation was introduced to remove a 218 glycosylation site. Antigen binding fragments (Fabs) were prepared by digestion of IgGs with 219 HRV3C protease as described previously (22). Clade A/E 93TH057 gp120 core e was prepared as 220 reported previously (55). Fab-93TH057gp120 core e complexes were further purified using 221
Superdex 200 16/60 (GE Healthcare) and concentrated to ~10 mg/ml in buffer containing 2.5 222 mM Tris-HCl, pH 7.5, 350 mM NaCl, 0.02% NaN 3 . Initial crystallizations were performed using 223 ethylene glycol, 15% glycerol, 7.5% 2R,3R-butanediol, and supplemented with reservoir 231 solutions. Data were processed using HKL2000 (56). The structures were determined by 232 molecular replacement using Phaser (57) and VRC01-bound 93TH057gp120 (PDB ID: 3NGB) 233 as the search model. Models were rebuilt manually using COOT (58) and refinement was 234 performed with PHENIX (59). The program PISA (60) was used to calculate binding surfaces. 235
236
Structure-guided optimizations 237
Design of VRC07 heavy chain interface mutants. All VRC07-gp120 interface residues of the Ab 238 were considered for mutation. For each amino acid position, structure-based design was 239 conducted using OSPREY (61, 62). The top-ranked OSPREY mutants were visualized for gained 240 interface interactions using Probe (63) and selected for mutagenesis. 241
242
Design of VRC07 partial framework reversions to germline. A method for partial reversion of 243 antibody residues to germline was used as described (64). Specific amino acids in the variable 244 heavy and variable light framework regions were chosen for reversion to germline. Structural 245 analysis and structure-based design were performed using OSPREY (61, 62), MolProbity (65), 246
and PyMOL (The PyMOL Molecular Graphics System, Version 1.5.0.4, Schrödinger, LLC). 247 on July 10, 2017 by guest http://jvi.asm.org/
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Design of VRC07 mutants with altered hydrophobic residues. Hydrophobic residues that were 249 exposed on the VRC07 surface but that were not part of the antibody-gp120 interface were 250 selected for mutation. Solvent-accessible surface area for each residue was computed using 251 ASA-View (66) and antibody-antigen analysis was performed using PISA (60). Additional 252 mutations to Asp or Glu in the CDR H2 and CDR L1 were introduced to improve biophysical 253 properties (67). Structure-based antibody redesign and mutation scoring was performed using 254
OSPREY (61, 62). 255 256
Redesign of VRC07 light-heavy chain interface. The following VRC07 light chain residues at the 257 interface with the antibody heavy chain, but not proximal to gp120, were selected for redesign: 258 Ala34, Ala43, Leu46, Ala55, and Ala56. The OSPREY protein redesign software (61, 62) was 259 used to search for and select mutations at these residue positions that may stabilize the VRC07 260 light-heavy chain interface. 261
262
Design of G54 mutants. Initially, G54 variants were selected based on information gained from 263 previous reports (19, 26, 68) and current structural studies. The rationale was to select residues 264 with bulky hydrophobic side chains, such as Phe, Trp, or Tyr, that will allow mimicry of the 265 gp120-Phe 43 CD4 interaction. The initial G54F, G54W, and G54Y variants showed increased 266 potency and breadth, but also showed strong autoreactivity. Thus, we generated variants with all 267 possible amino acids at this location and tested their neutralization potency/breadth and 268 autoreactivity. blocked with PBS-T buffer containing 5% skim milk (Thermo Fisher) and 2% bovine albumin 296 fraction V (MP Biomedicals, Santa Ana, CA) for 1 hour at room temperature (RT) or overnight 297 at 4°C, followed by incubation with antibody serially diluted in PBS-T buffer for 1 hour at RT. 298
Horseradish peroxidase-conjugated sheep anti-human IgG antibody (GE Healthcare) at 1:5,000 299 was added for 1 hour at RT. All volumes were 100 μl/well except that 200 μl/well was used for 300 blocking. Plates were washed five times between each step with PBS-T. After final wash, plates 301 were developed using 100 μl/well of 3,3´,5,5´-tetramethylbenzidine (TMB) (Kirkegaard & Perry 302
Laboratories, Gaithersburg, MD ), stopped using 50 μl/well of 0.5 M NaOH, and read at 450 nm. 303 304
Polyreactivity analysis of antibodies 305
Antibody binding to cardiolipin was determined as previously described (73). Briefly, using the 306 QUANTA Lite ACA IgG III ELISA kit (Zeus Scientific) per manufacturer's protocol, each 307 antibody was diluted to 100 μg/ml in the kit sample diluent and tested in 3-fold serial dilutions. 308
Results shown are representative of at least two independent ELISAs. Positive and negative 309 controls were included on each plate, and values three times above background were considered 310 positive. Antibody reactivity to a human epithelial cell line (HEp-2) was determined with the 311 ANA/HEp-2 Cell Culture IFA Test System (Zeus Scientific) per manufacturer's protocol and as 312 previously described (73). Antibodies were diluted to 50 μg/ml and 25 μg/ml in ZOBRA-NS 313 diluent. Positive and negative controls were included on each slide. Antibodies were scored 314 
Pharmacokinetics in non-human primates 325
Indian rhesus macaques were infused intravenously with 10 mg/kg of mAb. Endotoxin levels 326
were measured for each antibody preparation by the QCL-1000™ endpoint chromogenic LAL 327 assay (Lonza) and were all below 0.5 EU/mg levels. Whole blood samples were collected prior 328 to injection, and at time points 0, 30 mins, 6 hours, 12 hours, and days 1, 2, 4, 7, 14, 21, and 28. were included on each plate. Plasma was incubated on the plate for 1 h at RT, followed by a 342 PBS-T wash. Bound mAbs were probed with a horseradish peroxidase-labeled goat anti-human 343
Pharmacokinetic calculations 350
Pharmacokinetic parameters were calculated by WinNonlin software (Pharsight) using a non-351 compartmental model. 352
353
Mucosal sampling 354
Rectal mucosa samples were collected by Weck-Cel sponges (Beaver Visitec) (5). Three samples 355 were collected per animal per time point, and sponges were stored at -80°C until processing. All 356 samples with visible blood were discarded. To elute mucosal sample, sponges were placed in 357
Spin-X columns (Corning) on ice, 300 μl chilled elution buffer (PBS with Proteases Inhibitor, 358 10% Igepal, and 0.25% BSA) was added, and samples were spun at 13,000 x g for 15 min at 359 4°C. mAb levels in eluted mucosa samples were quantified by RSC3 ELISA. family-specific primers yielded mostly heavy chain transcripts related to VRC03, but four 398 sequences were similar to VRC01 (26) (Supplementary Fig. 1 ). Two of these were identical, 399 revealing a heavy chain sequence that shared 90% nucleotide sequence identity to VRC01, but 400 differing at 15 amino acid positions and containing a four amino acid insertion in the heavy chain 401 third complementarity determining region (CDR H3) (Fig. 1a) . While the natural light chain 402 partner of this sequence was not obtained from heavy chain PCR amplification and 403 pyrosequencing, our previous studies demonstrated efficient light chain complementation among 404 VRC01 class antibodies (26). Thus, this heavy chain was paired with the original VRC01 light 405 chain for protein expression as a full IgG1. The resulting mAb was named VRC07. 406
The neutralization activity of VRC07 was assessed on a panel of 179 diverse HIV-1 Env-407 pseudoviruses that included 20 VRC01-resistant strains. mAb NIH45-46, another clonal variant 408 of VRC01, was included for comparison because it also contains a four amino acid CDR H3 409 insert (24) similar to VRC07 (Fig. 1a) . VRC07 neutralized a greater fraction of viruses than 410 VRC01 or NIH45-46 at all tested concentrations (Fig. 1b) . Overall, VRC07 neutralized 93% of 411 strains with an IC 50 less than 50 μg/ml and 83% of strains with an IC 50 less than 1 μg/ml and was 412 able to neutralize eight of 20 VRC01-resistant viruses (Table 1, Supplementary Fig. 2) . Among 413 on July 10, 2017 by guest http://jvi.asm.org/ Downloaded from the viruses that were neutralized, VRC07 displayed ~2-fold higher potency than VRC01, with a 414 geometric mean 50% inhibitory concentration (IC 50 ) of 0.11 μg/ml (Fig. 1c and Supplementary  415 
Fig. 2). 416
To understand VRC07 binding at the atomic level, we determined the crystal structure of 417 VRC07 in complex with a clade A/E core gp120 (Supplementary Table 1 ). An overlay of the 418 VRC07-gp120 structure with that of the VRC01-gp120 structure (20) revealed that these 419 antibodies have the same modes of gp120 recognition (Fig. 1d) . However, similar to what was 420 described for NIH45-46 (48), the extended CDR H3 of VRC07 created new contacts between 421 gp120 and residues R100a, D100b, and Y100c of VRC07 (Fig. 1d,e) , doubling the CDR H3-422 mediated contact area relative to that of VRC01 (Supplementary Fig. 3) . 423 424
Structure-guided optimizations improve the neutralization potency of VRC07 in vitro 425
Although VRC07 was potent in HIV-1 neutralization assays (Supplementary Fig. 2) , we 426 sought to engineer additional increases in neutralization potency and breadth (Fig. 2) . 427
Previously, Diskin, Bjorkman and colleagues altered a single heavy chain glycine residue to 428 tryptophan (G54W) to mimic the interaction between the phenylalanine (F43) of CD4 and a 429 hydrophobic binding pocket region on gp120 (77). This modification increased the potency and 430 breadth of NIH45-46 (68). Our structural studies on the clonal variant VRC03 also showed that 431 position 54 contained a natural tryptophan that mimicked the gp120-F43 CD4 binding (26). We 432 thus began by adding this tryptophan mutation to VRC07. Consistent with the observations for 433 NIH45-46 (68), we observed an increase in binding to gp120 by ELISA and enhanced 434 neutralization potency for VRC07-G54W (Supplementary Fig. 4a) . We crystallized the 435 VRC07-G54W variant with an HIV-1 gp120 core and confirmed that the tryptophan residue 436 on July 10, 2017 by guest http://jvi.asm.org/ Downloaded from increases contact area with gp120 (Supplementary Fig. 4b) . Unfortunately, the VRC07-G54W 437 variant reacted positively in two assays of autoreactivity (73), anti-nuclear antibody staining of 438 human epithelial (HEp-2) cells and binding to cardiolipin (Fig. 3) . 439
To determine whether an alternative amino acid at position 54 could increase potency 440 without increasing autoreactivity, we performed a comprehensive mutational analysis for 441 position 54, testing all 20 amino acids ( Supplementary Fig. 4 and Supplementary Table 2) . 442
Many VRC07 variants with hydrophobic or positively charged amino acids at position 54 443
showed enhanced binding to gp120 (Supplementary Fig. 4a ), but most of these substitutions 444 also resulted in similar autoreactivity to the G54W mutation. However, alteration of G54 to a 445 histidine resulted in increased potency and breadth with minimal levels of autoreactivity 446 (Supplementary Fig. 4c, d) . Further, the crystal structure of VRC07-G54H with gp120 revealed 447 that this histidine interacted with the target hydrophobic pocket in the gp120 CD4bs (Fig. 2a) . 448
Additional analysis of the interface between VRC07 and gp120 revealed that the N-terminal 449 residues of the light chain of VRC07 were in close proximity to the variable region 5 (V5) of 450 gp120 and were disordered (Fig. 2a) . This suggested that the N-terminus of the light chain did 451 not make critical contacts with gp120 and that the light chain may encounter steric hindrance 452 with V5. The V5 region often contains both sequence and length variations, suggesting that 453 divergent HIV-1 strains with V5 insertions could also clash with the VRC07 light chain N-454 terminus. We therefore generated antibody variants with modifications of the four most N-455 terminal residues of the VRC07 light chain. These variants included amino acid deletions, 456 substitutions to amino acids with smaller side chains, and combinations of both (Supplementary 457 Fig. 5 and Supplementary Table 2) . Most of the deletions increased neutralization potency, but 458 many also increased autoreactivity. A two amino acid deletion (E1 and I2) along with a 459 substitution of the third residue from valine to serine (V3S) increased potency ~2.5-fold (~7-fold 460 increase over VRC01) on a representative 20 virus neutralization panel, while not altering 461 autoreactivity (Supplementary Fig. 5) . 462
Additionally, we explored mutations that altered the heavy chain/light chain interface, the 463 antibody/antigen interface, the hydrophobicity profile of the antibody, sites of N-linked 464 glycosylation, and reversions to germline residues (64) (Supplementary Table 2) . From these 465 analyses, we identified two sets of mutations to include in the lead optimized candidates: 466 framework region germline reversions in the heavy chain (mutations I37V/T93A) and a 467 combination of five mutations in the light chain named hpL02 designed to increase solubility 468 (four hydrophobic to hydrophilic amino acid mutations on the surface of the antibody -469 mutations I20T, W67S, V106Q, I108N --plus a mutation to remove an N-linked glycosylation 470 site, N72T) (Fig. 2c) . Bjorkman and colleagues (48) identified a light chain mutation (S28Y) in 471 NIH45-46-G54W that increases potency; however, a tyrosine was already present in this position 472 in VRC07 (and VRC01). 473
From initial neutralization and autoreactivity screening assays, we selected four 474 optimized candidates for detailed characterization (Figs. 2 and 3) , including assessment of 475 autoreactivity and neutralization breadth and potency on a large panel of 179 viral strains 476 (Supplementary Fig. 6 ). All four VRC07 optimized antibodies demonstrated increased breadth 477 and potency compared with VRC01 and VRC07 ( Fig. 2c and Supplementary Fig. 6 ). These 478 changes improved the overall breadth to 96% and, based on geometric mean IC 50 and IC 80 479 values, increased potency 4.4-to 7.9-fold compared to VRC01 ( Table 1) . VRC07-523, the most 480 potent of the engineered variants, was 7.9-fold more potent than VRC01 on the basis of 481 geometric mean IC 50 values ( Table 1) . VRC07-501 and VRC07-508 both displayed moderate 482 on July 10, 2017 by guest http://jvi.asm.org/ Downloaded from autoreactivity (scoring 1+ on the HEp-2 assay when tested at a concentration of 25 μg/ml), 483 although they were less autoreactive than VRC07-G54W (which scored 2+ at the same 484 concentration), while VRC07-523 and VRC07-544 both had minimal autoreactivity (and scored 485 negative when tested at 25 μg/ml) (Fig. 3) . 486 487
Pharmacokinetics of VRC07 variants in non-human primates 488
We investigated the plasma half-life of the optimized VRC07 variants in Indian-origin 489 rhesus macaques (Fig. 4a,d and Supplementary Fig. 7a ). While infusion of human antibodies 490 into monkeys generally results in a shorter half-life (78) than the typical 21 day average half-life 491 of IgG1 in humans (79), the NHP model is often used for comparative pharmacokinetic studies 492 as a guide to selection of agents for human testing. Published data suggested that antibody 493 autoreactivity reduces circulating plasma half-life (80). We therefore first compared the 494 pharmacokinetics of wild type VRC07 to the highly autoreactive variant VRC07-G54W. Using 495 standard measures of antibody plasma half-life, area under the curve and clearance, VRC07-496 G54W displayed circulating levels ~2-fold less than wild type VRC07. 497
To improve the plasma half-life of VRC07, we incorporated a previously described set of 498 2 amino acid mutations (M428L/N434S, referred to as LS) that increase half-life by increasing 499 affinity for the neonatal Fc-receptor (FcRn), which results in recirculation of functional IgG (74, 500 78). The VRC07-LS mutant displayed a 2-to 3-fold increase in plasma half-life compared with 501 wild type VRC07 in rhesus macaques (Fig. 4b,d) . Based on these data, the four optimized 502 VRC07 variants were constructed with this LS mutation, and the pharmacokinetic properties of 503 these antibodies were assessed in vivo. Among the four variants, VRC07-523-LS displayed a 504 longer half-life (9.8 days) than the other three variants, close to the half-life of VRC07-LS (11.6 505 on July 10, 2017 by guest http://jvi.asm.org/ Downloaded from days). For all four optimized variants, the plasma mAb levels and half-lives in rhesus macaques 506
were intermediate between that of VRC07 and VRC07-LS (Fig. 4c,d) . When mAb levels in 507 rectal mucosal secretions were measured, antibody VRC07-523-LS was detectable for at least 14 508 days (Supplementary Fig. 7b) . 509 510
Optimized VRC07 protects against infection at lower plasma concentrations 511
To determine if an antibody with increased neutralization potency in vitro would confer 512 greater in vivo protection, we compared the ability of VRC01-LS and VRC07-523-LS to protect 513 rhesus macaques from intra-rectal challenge with SHIV BaLP4. We assessed the neutralization 514 sensitivity of the SHIV BaLP4 challenge stock to both antibodies. VRC07-523-LS neutralized 515 SHIV BaLP4 at a 5.6-fold lower concentration than VRC01 (IC 50 values of 0.028 μg/ml and 516 0.005 μg/ml respectively) (Fig. 5a, b) . Challenge experiments were designed using varied 517 antibody infusion doses to allow a calculation of the plasma mAb concentration that provides 518 50% protection (plasma EC 50 ). mAbs were administered intravenously and animals were 519 challenged mucosally five days later. This approach allowed us to compare the effective plasma 520 concentration of VRC07-523-LS and VRC01-LS at the time of SHIV challenge, irrespective of 521 the infusion dose. When VRC07-523-LS was administered at doses of 0.2 mg/kg and 0.05 522 mg/kg, 3 of 4 animals and 0 of 4 animals were protected, respectively. For VRC01-LS, 5 of 12 523 animals were protected at a dose of 0.3 mg/kg ( Fig. 5c and Supplementary Fig. 8 ). We 524 measured plasma antibody levels at the time of SHIV challenge and used a binary (probit) 525 regression model to calculate the EC 50 values: the EC 50 values for VRC07-523-LS and VRC01-526 LS were 0.47 μg/ml and 2.5 μg/ml respectively, and the 90 confidence intervals for these values 527 did not overlap (Fig. 5d) . This difference in the regression curves for VRC01-LS and VRC07-528 have renewed interest in testing mAbs in clinical trials (13, 82, 83) . The overall efficacy of an 537 HIV-1 mAb likely depends on several characteristics, including the breadth of reactivity (i.e., the 538 fraction of circulating virus strains neutralized), the neutralization potency (i.e., the concentration 539 of antibody needed to prevent infection), and the pharmacokinetic properties (e.g., circulating 540
half-life and tissue localization). Here, we sought to improve the potency and breadth of antibody 541 VRC01 and used the resulting antibody to demonstrate a relationship between in vitro 542 neutralization potency and in vivo efficacy. Additionally, we improved the half-life both by 543 minimizing autoreactivity and by adding Fc-region mutations that increase circulating plasma 544 mAb levels. Thus, our lead candidate, VRC07-523-LS, was engineered to have the in vitro and 545 in vivo characteristics likely to increase clinical protective efficacy. 546
Our studies started with the well-characterized mAb VRC01, which has high in vitro 547 potency and breadth and is currently being evaluated in phase I clinical trials. Using deep 548 sequencing and bioinformatics, we identified a heavy chain VRC01 clonal variant from donor 45 549 with moderately improved potency and breadth. Structure-based analyses were used to design 550 variants with improved neutralization activity. Numerous mutations were explored, and 551 mutations focused on the heavy chain G54 residue and the N-terminus of the light chain were 552 found to have the most favorable in vitro characteristics. In combination, a G54H point mutation 553 on the heavy chain, a deletion of the two N-terminal light chain amino acids (E1 and I2), and a 554 V3S point mutation on the light chain led to a 5-to 8-fold increase in neutralization potency 555 Notably, these mutations improved potency without causing substantial autoreactivity. 558
This was particularly important because autoreactivity and off-target binding may decrease 559 plasma mAb levels and potentially promote unwanted immunopathology. For example, in human 560 clinical trials, infusion of a combination of the gp41 mAbs 4E10 and 2F5 that are both 561 autoreactive (73), and 2G12, which is not autoreactive, was associated with a prolonged in vitro 562 blood clotting time (partial thromboplastin time) (84). In the same studies, mAbs 4E10 and 2F5 563 both had shorter half-lives than the non-autoreactive mAb 2G12 (73, 84-86). Additionally, 564 during the development of motavizumab, a second generation anti-RSV mAb, autoreactivity 565 (broad tissue binding and cross-reactivity) was also associated with lower circulating plasma 566
levels (87). 567
To compare pharmacokinetic properties, including circulating plasma half-life, VRC07 568 variants were analyzed in rhesus macaques. These experiments confirmed that the autoreactive 569 mAb VRC07-G54W had a shorter half-life than VRC07. These in vivo data suggested an 570 association between antibody autoreactivity and shorter half-life and provided further rationale 571 for pursuing VRC07 variants with the heavy chain G54H mutation, which showed low levels of 572 autoreactivity. We constructed the optimized VRC07 variants (VRC07-501, VRC07-508, 573 VRC07-523 and VRC07-544) with a two amino acid "LS" mutation in the IgG Fc region that has 574 been shown to increase affinity for FcRn and to increase antibody half-life in vivo (78) . We 575 recently demonstrated that mAb VRC01-LS, with enhanced FcRn binding, displayed increased 576 gut mucosal tissue localization which improved protection against SHIV infection in the NHP 577 on July 10, 2017 by guest http://jvi.asm.org/ Downloaded from model (74). Our preferred variant, VRC07-523-LS, displayed a >2-fold improved half-life 578 compared to the wild type VRC07 without the LS mutation. 579
In vitro neutralization is often assumed to be the most important predictive factor in 580 protection against in vivo lentiviral infection; however, some studies have suggested a role of Fc-581 mediated effector functions such as antibody-dependent cellular cytotoxicity (ADCC) in 582 protection (88, 89). Of note, the LS mutations introduced into the CH3 domain do not affect 583 ADCC activity (74, 78). While we did not address the role of ADCC here, we were able to 584 directly address the relationship of in vitro neutralization potency and in vivo efficacy. Thus, we 585 compared the ability of VRC01-LS and the optimized VRC07-523-LS to protect NHPs from 586 mucosal SHIV challenge. VRC01-LS and VRC07-523-LS were administered at low doses to 587 monkeys that were then challenged with SHIV BaLP4. VRC07-523-LS was able to protect at 588 levels 5 times lower than VRC01-LS. Although the differences in protection were slightly above 589 the threshold for statistical significance, we believe our results strongly suggest a relationship 590 between in vitro and in vivo potency. Notably, the ~5-fold difference in protection was 591 comparable to that seen in neutralization assays in vitro. 592
In summary, we show that a process of iterative structure-based design and in vitro 593 analyses improved the neutralization activity of VRC01, a mAb that targets the CD4bs of the 594 HIV-1 envelope glycoprotein gp120. VRC01 is able to neutralize 89% of HIV-1 strains with a 595 geometric mean IC 50 of 0.22 μg/ml. The optimized VRC07-523 neutralized 96% of HIV-1 596 
